Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Valirx plc (VAL) ORD GBP0.001

Sell:21.00p Buy:22.50p 0 Change: 1.75p (7.45%)
Market closed Prices as at close on 28 October 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:21.00p
Buy:22.50p
Change: 1.75p (7.45%)
Market closed Prices as at close on 28 October 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:21.00p
Buy:22.50p
Change: 1.75p (7.45%)
Market closed Prices as at close on 28 October 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Contact details

Address:
180-186 Kings Cross Road
LONDON
WC1X 9DE
United Kingdom
Telephone:
+44 (020) 30084416
Website:
www.valirx.com

Important dates

Future events
There are no future events available.
Past events
Interim results 07 September 2020 07/09/20
AGM 23 July 2020 23/07/20
Final results 01 July 2020 01/07/20
General meeting 22 May 2020 22/05/20
General meeting 17 February 2020 17/02/20

General stock information

EPIC:
VAL
ISIN:
GB00BLH13C52
Market cap:
£13.93 million
Shares in issue:
64.03 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Suzanne Dilly
    Chief Executive Officer
  • Gerald Desler
    Chief Financial Officer, Director
  • Kevin Alexander
    Secretary, Non-Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.